<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253643</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000443617</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-CI-CPC-04131-LX</secondary_id>
    <secondary_id>VAMC-04-0303/ M1016</secondary_id>
    <secondary_id>DOD-W81XWH-04-1-0296</secondary_id>
    <secondary_id>OHSU-1117</secondary_id>
    <secondary_id>KPNW-NW-05SLIEB-01</secondary_id>
    <nct_id>NCT00253643</nct_id>
  </id_info>
  <brief_title>Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer</brief_title>
  <official_title>Catechins and Omega-3 Fatty Acids Impact on Fatty Acid Synthase Activity in the Prostate: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,
      or coming back. The use of fish oil and/or green tea may prevent prostate cancer.

      PURPOSE: This randomized clinical trial is studying how well a fish oil and/or green tea
      supplement works in preventing prostate cancer in patients with prostatic intraepithelial
      neoplasia or who are at risk for developing prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the cancer preventing effects of fish oil supplementation and green tea
           extract use on markers of alteration in lipid metabolism in prostate tissue samples.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
      stratified according to age (under 65 vs 65 and over). Patients are randomized to 1 of 4
      treatment arms.

        -  Arm I: Patients receive oral fish oil three times daily and oral green tea extract twice
           daily.

        -  Arm II: Patients receive an oil placebo three times daily and oral green tea extract
           twice daily.

        -  Arm III: Patients receive oral fish oil three times daily and a placebo twice daily.

        -  Arm IV: Patients receive an oil placebo three times daily and another placebo twice
           daily.

      Treatment in one of the above-listed arms continues for up to 20 weeks in the absence of
      disease progression or unacceptable toxicity.

      All patients undergo a prostate biopsy on the last day of study treatment.

      After completion of study treatment, patients receive a follow-up phone call at/around 30
      days later.

      PROJECTED ACCRUAL: A total of 144 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatty Acid Synthase Expression by Immunohistochemistry at Pre- and Post-intervention (FAS Summary Score)</measure>
    <time_frame>Baseline (pre-intervention) and end of study (time to surgery for those with malignant findings or up to 8 weeks for those with benign biopsies, post-intervention)</time_frame>
    <description>Sections of paraffin-embedded prostate biopsy tissue were stained for fatty acid synthase (FAS) expression. The FAS Summary Score was calculated as the product of percent stained (1=0-25%, 2=25-50%, 3=51-75%, 4=76-100%) and stain intensity (0-3) by immunohistochemistry. The range of the product is 0-300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell Proliferation by Ki67-immunohistochemistry at Pre- and Post-intervention</measure>
    <time_frame>End of study</time_frame>
    <description>Cell Proliferation by Ki67 is calculated as the percent stained by immunohistochemistry. Ki-67 values were log-transformed because the original distribution was skewed. Analysis was done on log-base2 transformed values.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Precancerous Condition</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (FO, GT catechin extract)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ArmII (FO placebo, GT catechin extract)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (FO, GT placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (FO placebo, GT placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>green tea catechin extract</intervention_name>
    <description>Given orally 2 times/day</description>
    <arm_group_label>Arm I (FO, GT catechin extract)</arm_group_label>
    <arm_group_label>ArmII (FO placebo, GT catechin extract)</arm_group_label>
    <other_name>Polyphenon E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fish oil</intervention_name>
    <description>Given orally 3 times/day</description>
    <arm_group_label>Arm I (FO, GT catechin extract)</arm_group_label>
    <arm_group_label>Arm III (FO, GT placebo)</arm_group_label>
    <other_name>omega-3 fatty acid, n-3 fatty acid, omega-3 polyunsaturated fatty acid, omega-3 PUFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given olive oil placebo orally 3 times/day</description>
    <arm_group_label>Arm III (FO, GT placebo)</arm_group_label>
    <arm_group_label>Arm IV (FO placebo, GT placebo)</arm_group_label>
    <other_name>PLCB, olive oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given green tea placebo orally 2 times/day</description>
    <arm_group_label>ArmII (FO placebo, GT catechin extract)</arm_group_label>
    <arm_group_label>Arm IV (FO placebo, GT placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Clinician recommends repeat biopsy of the prostate (&quot;Repeat&quot; is defined as any
             recommended biopsy of the prostate subsequent to an earlier biopsy of the prostate)

        EXCLUSION CRITERIA:

          -  Definitive invasive prostate cancer on initial biopsy

          -  Significant active medical illness that in the opinion of the clinician would preclude
             protocol treatment.

          -  History of ventricular tachycardia or ventricular fibrillation

          -  Subject reported use of fish oil (greater than 1 gram per day) or green tea supplement
             within 30 days before Day 1 of study treatment

          -  Subject reported use of fish oil â‰¤ 1 gram per day and unwilling to discontinue use for
             the duration of the trial

          -  Use of warfarin or need for therapeutic anticoagulation at time of biopsy or at
             anytime during the course of the trial.

          -  Subject reported allergy or sensitivity to fish oil, olive oil or green tea

          -  Subject reported history of hemophilia, van Willebrands disease or other bleeding
             disorder, except when the subject is evaluated by a hematologist who determines that
             fish oil supplementation is not contraindicated.

          -  Total bilirubin greater than institutional upper limit of normal

          -  Concurrent high risk study participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jackilen Shannon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Center for Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>February 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2015</results_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jackie Shannon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>precancerous condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Fish Oil, Green Tea Catechin Extract)</title>
          <description>Patients receive oral fish oil 3/day and oral green tea extract 2/day
green tea catechin extract: Given orally 2 times/day
fish oil: Given orally 3 times/day
laboratory biomarker analysis: Correlative studies
questionnaire administration: Ancillary studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Fish Oil Placebo, Green Tea Catechin Extract)</title>
          <description>Patients receive an oil placebo 3/day and oral green tea extract 2/day
green tea catechin extract: Given orally 2 times/day
placebo: Given olive oil placebo orally 3 times/day
laboratory biomarker analysis: Correlative studies
questionnaire administration: Ancillary studies</description>
        </group>
        <group group_id="P3">
          <title>Arm III (Fish Oil, Green Tea Placebo)</title>
          <description>Patients receive oral fish oil 3/day and a placebo mimicking green tea catechins 2/day
fish oil: Given orally 3 times/day
placebo: Given green tea placebo orally 2 times/day
laboratory biomarker analysis: Correlative studies
questionnaire administration: Ancillary studies</description>
        </group>
        <group group_id="P4">
          <title>Arm IV (Fish Oil Placebo, Green Tea Placebo)</title>
          <description>Patients receive an oil placebo mimicking fish oil 3/day and another placebo mimicking green tea catechins 2/day
placebo: Given olive oil placebo orally 3 times/day
placebo: Given green tea placebo orally 2 times/day
laboratory biomarker analysis: Correlative studies
questionnaire administration: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Fish Oil, Green Tea Catechin Extract)</title>
          <description>Patients receive oral fish oil 3/day and oral green tea extract 2/day
green tea catechin extract: Given orally 2 times/day
fish oil: Given orally 3 times/day</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Fish Oil Placebo, Green Tea Catechin Extract)</title>
          <description>Patients receive an oil placebo 3/day and oral green tea extract 2/day
green tea catechin extract: Given orally 2 times/day
placebo: Given olive oil placebo orally 3 times/day</description>
        </group>
        <group group_id="B3">
          <title>Arm III (Fish Oil, Green Tea Placebo)</title>
          <description>Patients receive oral fish oil 3/day and a placebo mimicking green tea catechins 2/day
fish oil: Given orally 3 times/day
placebo: Given green tea placebo orally 2 times/day</description>
        </group>
        <group group_id="B4">
          <title>Arm IV (Fish Oil Placebo, Green Tea Placebo)</title>
          <description>Patients receive an oil placebo mimicking fish oil 3/day and another placebo mimicking green tea catechins 2/day
placebo: Given olive oil placebo orally 3 times/day
placebo: Given green tea placebo orally 2 times/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Benign</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostatic Intraepithelial Neoplasia (PIN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fatty Acid Synthase Expression by Immunohistochemistry at Pre- and Post-intervention (FAS Summary Score)</title>
        <description>Sections of paraffin-embedded prostate biopsy tissue were stained for fatty acid synthase (FAS) expression. The FAS Summary Score was calculated as the product of percent stained (1=0-25%, 2=25-50%, 3=51-75%, 4=76-100%) and stain intensity (0-3) by immunohistochemistry. The range of the product is 0-300.</description>
        <time_frame>Baseline (pre-intervention) and end of study (time to surgery for those with malignant findings or up to 8 weeks for those with benign biopsies, post-intervention)</time_frame>
        <population>Number of participants for recruitment was based on power calculations. All participants consented and randomized were included in analyses. Analysis was intention to treat. No imputations for missing data were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Fish oil, Green Tea catechin extract</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Fish oil placebo, Green Tea catechin extract</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Fish oil, Green Tea placebo</description>
          </group>
          <group group_id="O4">
            <title>Arm IV</title>
            <description>Fish oil placebo, Green Tea placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fatty Acid Synthase Expression by Immunohistochemistry at Pre- and Post-intervention (FAS Summary Score)</title>
          <description>Sections of paraffin-embedded prostate biopsy tissue were stained for fatty acid synthase (FAS) expression. The FAS Summary Score was calculated as the product of percent stained (1=0-25%, 2=25-50%, 3=51-75%, 4=76-100%) and stain intensity (0-3) by immunohistochemistry. The range of the product is 0-300.</description>
          <population>Number of participants for recruitment was based on power calculations. All participants consented and randomized were included in analyses. Analysis was intention to treat. No imputations for missing data were conducted.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRE data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" spread="98.6"/>
                    <measurement group_id="O2" value="158.8" spread="84.6"/>
                    <measurement group_id="O3" value="138.3" spread="63.8"/>
                    <measurement group_id="O4" value="102.3" spread="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POST data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.7" spread="100.3"/>
                    <measurement group_id="O2" value="159.3" spread="75.5"/>
                    <measurement group_id="O3" value="145.2" spread="72.2"/>
                    <measurement group_id="O4" value="152.2" spread="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed effects model to assess the effect time (pre vs. post) and treatment (GTFO, GT, FO and Placebo) on FAS summary scores</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1521</p_value>
            <p_value_desc>Utilized a priori threshold for statistical significance of 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cell Proliferation by Ki67-immunohistochemistry at Pre- and Post-intervention</title>
        <description>Cell Proliferation by Ki67 is calculated as the percent stained by immunohistochemistry. Ki-67 values were log-transformed because the original distribution was skewed. Analysis was done on log-base2 transformed values.</description>
        <time_frame>End of study</time_frame>
        <population>Number of participants for recruitment was based on power calculations. All participants consented and randomized were included in analyses. Analysis was intention to treat. No imputations for missing data were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Fish oil, Green Tea catechin extract</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Fish oil placebo, Green Tea catechin extract</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Fish oil, Green Tea placebo</description>
          </group>
          <group group_id="O4">
            <title>Arm IV</title>
            <description>Fish oil placebo, Green Tea placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cell Proliferation by Ki67-immunohistochemistry at Pre- and Post-intervention</title>
          <description>Cell Proliferation by Ki67 is calculated as the percent stained by immunohistochemistry. Ki-67 values were log-transformed because the original distribution was skewed. Analysis was done on log-base2 transformed values.</description>
          <population>Number of participants for recruitment was based on power calculations. All participants consented and randomized were included in analyses. Analysis was intention to treat. No imputations for missing data were conducted.</population>
          <units>%age of cells &amp; nuclei stained</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="1" upper_limit="55"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="52"/>
                    <measurement group_id="O3" value="10" lower_limit="0" upper_limit="45"/>
                    <measurement group_id="O4" value="12" lower_limit="1" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed effects model to assess the effect of time (pre vs. post) and treatment (GTFO, GT, FO and Placebo) on Ki-67</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1573</p_value>
            <p_value_desc>A priori threshold for statistical significance is 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected every month the subject was on study via questionnaire over the phone. We conducted a 30-day follow-up phone call and utilized our adverse event questionnaire to capture this information at baseline as well.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Fish Oil, Green Tea Catechin Extract)</title>
          <description>Patients receive oral fish oil 3/day and oral green tea extract 2/day
green tea catechin extract: Given orally 2 times/day
fish oil: Given orally 3 times/day</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Fish Oil Placebo, Green Tea Catechin Extract)</title>
          <description>Patients receive an oil placebo 3/day and oral green tea extract 2/day
green tea catechin extract: Given orally 2 times/day
placebo: Given olive oil placebo orally 3 times/day</description>
        </group>
        <group group_id="E3">
          <title>Arm III (Fish Oil, Green Tea Placebo)</title>
          <description>Patients receive oral fish oil 3/day and a placebo mimicking green tea catechins 2/day
fish oil: Given orally 3 times/day
placebo: Given green tea placebo orally 2 times/day</description>
        </group>
        <group group_id="E4">
          <title>Arm IV (Fish Oil Placebo, Green Tea Placebo)</title>
          <description>Patients receive an oil placebo mimicking fish oil 3/day and another placebo mimicking green tea catechins 2/day
placebo: Given olive oil placebo orally 3 times/day
placebo: Given green tea placebo orally 2 times/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gas/Flatulence (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Burping (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upset Stomach (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea/ Loose Stool (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Heartburn (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising (grade 2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jackilen Shannon</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-220-8262 ext 54868</phone>
      <email>shannoja@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

